Answers are grounded in this paper and cite their sources.
Direct acting antiviral therapies (DAAs), are currently the state of the art therapy of chronic Hepatitis C (CHC) giving hope particularly to patients with liver cirrhosis. The aim of the study was to investigate the ability to use baseline data as predictors of non-response to DAAs in patients with CHC.
No takes yet. Share an insight, caveat, or question.
Ibrahim et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: